Name: Danoprevir
Brand: Selleck Chemicals
SKU: S1183
Rating: 5 (22 reviews)

Jump to

Quality Control

Batch: S118301 DMSO]144 mg/mL]false]Ethanol]144 mg/mL]false]Water]Insoluble]false Purity: 99.94%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS
Datasheet

99.94

Related Targets	HDAC Caspase Proteasome Secretase MMP Cysteine Protease DPP Tyrosinase HIV Protease Serine Protease
Other HCV Protease Inhibitors	Lomibuvir (VX-222) Asunaprevir Tizoxanide PSI-6206 (GS-331007) Mecarbinate Tegobuvir Herba taxilli Extract 2'-C-Methylcytidine

Chemical Information, Storage & Stability

Molecular Weight	731.83	Formula	C₃₅H₄₆FN₅O₉S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	850876-88-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	ITMN-191, RG7227			Smiles	CC(C)(C)OC(=O)NC1CCCCCC=CC2CC2(NC(=O)C3CC(CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6

Solubility

In vitro
Batch:

DMSO : 144 mg/mL (196.76 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 144 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.600mg/ml (4.92mM)	Taking the 1 mL working solution as an example, add 50 μL of 72 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.210mg/ml (1.65mM)	Taking the 1 mL working solution as an example, add 50 μL of 24.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features	A peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV).
Targets/IC₅₀/Ki	HCV NS3/4A protease 0.2 nM-3.5 nM
In vitro	Danoprevir (0.29 nM) inhibits the reference genotype 1 NS3/4A protease half-maximally, but a high dose of this compound (10 μM) shows no appreciably inhibition in a panel of 79 proteases, ion channels, transporters, and cell surface receptors. It remains bound to and inhibits NS3/4A for more than 5 hours after its initial association. This chemical (45 nM) eliminates a patient-derived HCV genotype 1b replicon from hepatocyte-derived Huh7 cells with an EC50 of 1.8 nM. In HCV subgenomic replicon cell lines containing the individual mutations, V36M, R109K, and V170A substitutions confer little or no resistance to it, but the R155K substitution confers a high level (62-fold increase) of resistance to this compound. In Huh7.5 cells transfected with chimeric recombinant virus, it shows antiviral inhibition effects against HCV genotypes 1, 4 and 6 with IC50 of 2-3 nM, which are >100-fold lower than genotypes 2/3/5 (280-750 nM).
Kinase Assay	Continuous fluorescent resonance energy transfer (FRET) assay
Kinase Assay	The assay buffer contains 25 μM NS4A peptide, 50 mM Tris-HCl, pH 7.5, 15% vol/vol, 10 mM dithiothreitol, and 0.5 μM QXL520-labelled FRET substrate {Ac-DE-Dap(QXL520)-EE-Abu-ψ-[COO]-AS-Cys(5-FAMsp)-NH2}. K2040 enzyme (50 pM) is added to initiate the reaction. Reactions are set up in black 96-well plates, and fluorescence data is collected. Control reactions lacking inhibitors and enzyme are included. Initial rates are calculated from the linear phase of the reaction (up to 1 hour) and are used to obtain IC50. Recovery of activity from preformed this compound-NS3/4A complex is assessed by preincubating 10 nM NS3/4A with a two-fold excess of this chemical in 1× assay buffer for 15 min, followed by a rapid 200-fold dilution of the preformed complex into assay buffer containing substrate. A control reaction with the same final conditions without preincubation of NS3/4A and this compound is initiated by the addition of enzyme to an otherwise-complete reaction mixture. Additional control reactions lack either this chemical or NS3. The progress of the reactions is followed over 5 hours.
In vivo	Danoprevir (30 mg/kg) administered to rats or monkeys shows that its concentrations in liver 12 hours after dosing exceed the concentration of this compound required to eliminate replicon RNA from cells.
References	[1] https://pubmed.ncbi.nlm.nih.gov/18824605/ [2] https://pubmed.ncbi.nlm.nih.gov/18637752/ [3] https://pubmed.ncbi.nlm.nih.gov/21480315/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01714154	Completed	Healthy Volunteer	Hoffmann-La Roche	November 2012	Phase 1
NCT01592318	Completed	Healthy Volunteer	Hoffmann-La Roche	May 2012	Phase 1
NCT01588002	Completed	Healthy Volunteer	Hoffmann-La Roche	April 2012	Phase 1
NCT01519336	Completed	Healthy Volunteer	Hoffmann-La Roche	February 2012	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Danoprevir HCV Protease inhibitor

Chemical Structure

Molecular Weight: 731.83